Special aspects concerning the marketing authorization of RNA-based medicines

ISSN： 2195-2175

Source： PHARMAKON, Vol.3, Iss.4, 2015-07, pp. : 309-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RNA-based therapeutic strategies for cancer

By Read Martin L Stevenson Mark Farrow Paul J Barrett Lee B Seymour Leonard W

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 5, 2003-05 ,pp. : 627-638

Informa Healthcare

Access to resources Recommend Favorite

Chemical modifications of nucleic acids for RNA-based therapeutics

By Grünweller Arnold Hartmann Roland K.

PHARMAKON, Vol. 3, Iss. 4, 2015-07 ,pp. : 263-270

Govi-Verlag

Access to resources Recommend Favorite

RNA-Based Drugs: From RNA Interference to Short Interfering RNAs

Current Pharmaceutical Biotechnology, Vol. 5, Iss. 4, 2004-08 ,pp. : 361-368

Bentham Science Publishers

Access to resources Recommend Favorite

Marketing Authorization of Veterinary Medicinal Products in Poland

By Sztabinska-Koncka H. Lewicki J.

Regulatory Toxicology and Pharmacology, Vol. 26, Iss. 1, 1997-08 ,pp. : 129-133

Academic Press

Access to resources Recommend Favorite

Chemical modification of nucleic acids as a key technology for the development of RNA-based therapeutics

By Grünweller A. Hartmann R. K.

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 71, Iss. 1, 2016-01 ,pp. : 8-16

Govi-Verlag

Access to resources Recommend Favorite